Citigroup Maintains Buy on 10x Genomics, Raises Price Target to $75
Portfolio Pulse from Benzinga Newsdesk
Citigroup analyst Patrick Donnelly maintains a Buy rating on 10x Genomics (NASDAQ:TXG) and raises the price target from $65 to $75.
August 04, 2023 | 3:14 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Citigroup maintains a Buy rating on 10x Genomics and raises the price target from $65 to $75, indicating positive sentiment towards the stock.
The raised price target by Citigroup indicates a positive outlook for 10x Genomics. This could lead to increased investor confidence and potentially a rise in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100